Endevica Bio (formerly TCI Peptide Therapeutics) was founded in 2009 with a focus on peptides that affect the melanocortin system, which mammals use to regulate food intake and energy homeostasis. The company’s core focus is on a drug candidate known as TCMCB07, which is a potential treatment for cachexia in cancer patients. Cachexia, a wasting disorder that can result in significant weight loss, is common in patients with advanced cancers, AIDS and kidney failure.
Endevica Bio anticipates that clinical trials for TCMCB07 will begin in the fourth quarter of 2021.
To learn more about the company and its TCMCB07 candidate, we spoke with the company’s chief commercial officer, LeAnn Kuhlmann Qi. In the following interview, Kuhlmann Qi provides an overview of cachexia and the potential to reverse the condition and explains why a dog model of disease can be considerably more useful than a rodent model.
Drug Discovery &a…